Harbin Medisan Pharmaceutical Third Quarter 2024 Earnings: EPS: CN¥0.051 (vs CN¥0.024 in 3Q 2023)

Simply Wall St · 10/25 23:48

Harbin Medisan Pharmaceutical (SZSE:002900) Third Quarter 2024 Results

Key Financial Results

  • Revenue: CN¥315.1m (up 11% from 3Q 2023).
  • Net income: CN¥14.3m (up 80% from 3Q 2023).
  • Profit margin: 4.5% (up from 2.8% in 3Q 2023).
  • EPS: CN¥0.051 (up from CN¥0.024 in 3Q 2023).
earnings-and-revenue-history
SZSE:002900 Earnings and Revenue History October 25th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Harbin Medisan Pharmaceutical shares are up 4.9% from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 3 warning signs for Harbin Medisan Pharmaceutical you should be aware of.